Search
ATOMIC Ears Study
Pneumococcal Vaccine Study
Noeletta McKenzie is a Champion for Change, RHDAustralia, and community representative and advocate for the START study.
Liana’s story begins nine years ago. It starts with a sore ankle, a fever, a trip to the emergency room and clinic and finally a diagnosis of acute rheumatic fever (ARF).
News & Events
Old, painful rheumatic heart disease treatment could be phased outAn international trial reveals 95% of rheumatic heart disease patients prefer less painful penicillin injections under the skin, aiming to improve treatment adherence.
News & Events
Unified response critical to address spread of ‘flesh eating’ bacteriaA surge in invasive group A streptococcal reports in Australia has prompted The Kids Research Institute Australia researchers to call for a unified national public health response, with cases tipped to increase.
Contact us If you'd like to get in touch, please contact Marie Nadal-Sims by phone or email. Phone: (08) 6319 1001 Email: IICPerth@thekids.org.au All media enquiries should be directed to Stacey Campbell, Communications Specialist for the Wesfarmers
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
Research
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY VaccineA MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.
Research
Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under: Addressing the Unknowns and Rationale for a Multicenter Clinical TrialBK polyomavirus infection in transplanted kidneys that leads to BK virus–associated nephropathy (BKVAN) is an important cause of allograft loss and has limited treatment options. Recent data suggest that BK viremia affects approximately 10% of people within the first 12 months following kidney transplantation. Among recipients with BKVAN, the overall risk of allograft loss is substantially increased, estimated to be 50% within 5 years of diagnosis.